Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451

Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451

AD is a progressive neurodegenerative disorder that is associated with the accumulation of two different insoluble protein aggregates, Aβ plaques and hyperphosphorylated tau. This study aimed to investigate the optimal acquisition and quantification of [18F]AV45 and [18F]AV1451 to image Aβ and tau,...

Descrición completa

Detalles Bibliográficos
Main Authors:	Firouzian, A, Whittington, A, Searle, G, Koychev, I, Zamboni, G, Lovestone, S, Gunn, R
Formato:	Journal article
Idioma:	English
Publicado:	SpringerOpen 2018

Títulos similares

Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451
por: Azadeh Firouzian, et al.
Publicado: (2018-03-01)

18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Niklas Mattsson, et al.
Publicado: (2017-07-01)

An updated radiosynthesis of [18F]AV1451 for tau PET imaging
por: Andrew V. Mossine, et al.
Publicado: (2017-06-01)

18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Richard M. Tsai, et al.
Publicado: (2019-01-01)

Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data
por: Suzanne L. Baker, et al.
Publicado: (2017-12-01)

Deep learning application for the classification of Alzheimer’s disease using 18F-flortaucipir (AV-1451) tau positron emission tomography
por: Sang Won Park, et al.
Publicado: (2023-05-01)

Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [18F]-AV-1451 PET data
por: Christina B. Young, et al.
Publicado: (2021-11-01)

Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case
por: Marta Marquié, et al.
Publicado: (2017-10-01)

Evaluation of the early-phase [18F]AV45 PET as an optimal surrogate of [18F]FDG PET in ageing and Alzheimer’s clinical syndrome
por: Matthieu Vanhoutte, et al.
Publicado: (2021-01-01)

Uptake of 18F-AV45 in the Putamen Provides Additional Insights into Alzheimer’s Disease beyond the Cortex
por: Zhengshi Yang, et al.
Publicado: (2024-01-01)

Optimization of Automatic Synthesis and Separation of [18F] AV-45 and Quality Control
por: Qi-Zhou Zhang, et al.
Publicado: (2022-04-01)

Automated Synthesis of 18F-AV45 for Aβ-Amyloid Imaging and its Preliminary Clinical Application
por: HUANG Zhenghai;REN Chao;ZHU Shikun;WANG Xuezhu;WU Meiqi;HUO Li
Publicado: (2021-08-01)

A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer's disease.
por: Julie Ottoy, et al.
Publicado: (2017-01-01)

Brain network alterations in individuals with and without mild cognitive impairment: parallel independent component analysis of AV1451 and AV45 positron emission tomography
por: Yuan Li, et al.
Publicado: (2019-06-01)

PET tau and amyloid-β burden in mild Alzheimer's disease: divergent relationship with age, cognition and cerebrospinal fluid biomarkers
por: Koychev, I, et al.
Publicado: (2017)

Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population.
por: Kuo-Lun Huang, et al.
Publicado: (2013-01-01)

The Pattern of Brain Amyloid Load in Posterior Cortical Atrophy Using 18F-AV45: Is Amyloid the Principal Actor in the Disease
por: Emilie Beaufils, et al.
Publicado: (2014-11-01)

Visual reading for [18F]Florzolotau ([18F]APN-1607) tau PET imaging in clinical assessment of Alzheimer’s disease
por: Huan-Chun Lin, et al.
Publicado: (2023-05-01)

In vivo imaging of tau deposition in Alzheimer’s disease using both [18F]-THK5317 and [18F]-S16: A pilot human study
por: Liping Fu, et al.
Publicado: (2022-08-01)

Tau accumulation in autosomal dominant Alzheimer’s disease: a longitudinal [18F]flortaucipir study
por: Antoinette O’Connor, et al.
Publicado: (2023-05-01)

Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Tessa Timmers, et al.
Publicado: (2019-07-01)

Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
por: Edmond Teng, et al.
Publicado: (2021-12-01)

First-in-human study of D6-[18F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [18F]FP-(+)-DTBZ (AV-133)
por: Ruiyue Zhao, et al.
Publicado: (2024-10-01)

18F-APN-1607 Tau Positron Emission Tomography Imaging for Evaluating Disease Progression in Alzheimer’s Disease
por: Xiaojun Xu, et al.
Publicado: (2022-02-01)

Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET
por: Shannon L. Risacher, et al.
Publicado: (2018-10-01)

Multicenter <sup>18</sup>F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease
por: Michael Rullmann, et al.
Publicado: (2022-03-01)

CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.
por: Rui Gao, et al.
Publicado: (2016-01-01)

PET imaging a MPTP-induced mouse model of Parkinson's disease using the fluoropropyl-dihydrotetrabenazine analog [18F]-DTBZ (AV-133).
por: James S Toomey, et al.
Publicado: (2012-01-01)

En kvalitativ studie av sykepleiestudenters opplevelser av nye læringsaktiviteter i kritisk vurdering av kvantitative forskningsartikler
por: Cecilie Katrine Utheim Grønvik, et al.
Publicado: (2015-01-01)

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result
por: Westwood, S, et al.
Publicado: (2018)

Integrated 18F-T807 Tau PET, Structural MRI, and Plasma Tau in Tauopathy Neurodegenerative Disorders
por: Cheng-Hsuan Li, et al.
Publicado: (2021-03-01)

Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography.
por: Aiko Ishiki, et al.
Publicado: (2015-01-01)

Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [18F]-S16 in Healthy Volunteers and Its Application in Assessment of Tau Pathology in Alzheimer’s Disease
por: Ying Wang, et al.
Publicado: (2022-02-01)

Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort
por: Matteo Tonietto, et al.
Publicado: (2024-11-01)

[18F]Tosyl fluoride as a versatile [18F]fluoride source for the preparation of 18F-labeled radiopharmaceuticals
por: Dong Zhou, et al.
Publicado: (2023-02-01)

Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics
por: Kocagoncu, E, et al.
Publicado: (2020)

18F-MK-6240 tau PET in patients at-risk for chronic traumatic encephalopathy
por: Michael L. Alosco, et al.
Publicado: (2025-02-01)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
por: Sarah Westwood, et al.
Publicado: (2018-12-01)

TMSOTf assisted synthesis of 2'-deoxy-2'-[18F]fluoro-β-D-arabinofuranosylcytosine ([18F]FAC).
por: Kishore K Gangangari, et al.
Publicado: (2018-01-01)

Optimizing the radiosynthesis of 6-[F-18]FDOPA using [F-18]Selectfluor
por: Forsback, S, et al.
Publicado: (2013)